8-K/A filed September 11, 2023, 7:59 PM ET ticker IRWD CIK 0001446847

other material confidence high sentiment neutral materiality 0.40

Ironwood files audited VectivBio financials: 2022 net loss $94M, 2021 & 2022 restated

IRONWOOD PHARMACEUTICALS INC

VectivBio 2022 revenue $27.3M from Asahi Kasei partner deal; net loss $94.1M.
VectivBio held $221.4M cash at Dec 31, 2022; total assets $252.6M.
Restated 2021 and 2022 statements to correct a misstatement; no further details here.
Pro forma combined results for Ironwood + VectivBio for H1 2023 and FY2022 included in filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.